


## GXF-111

Cat. No.:	HY-153414
Molecular Formula:	C <sub>42</sub> H <sub>42</sub> ClN <sub>7</sub> O <sub>3</sub>
Molecular Weight:	728.28
Target:	Epigenetic Reader Domain; PROTACs
Pathway:	Epigenetics; PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	GXF-111, a PROTAC molecule, can promote selective degradation of cellular BRD3 and BRD4-L. GXF-111 has binding affinities for BRD3 BD1 and BRD3 BD2 with K <sub>i</sub> values of 11.97 nM and 2.35 nM, respectively. GXF-111 can be used for the research of cancer <sup>[1]</sup> .												
<b>IC<sub>50</sub> &amp; Target</b>	Ki: 11.97 nM (BRD3 BD1); 2.35 nM (BRD3 BD2) <sup>[1]</sup> . IC50: 6.31 nM (MV4-11 cell); 95.2 nM (MM.1 S cell) <sup>[1]</sup> .												
<b>In Vitro</b>	<p>GXF-111 (Compound 24) has binding affinities for BRD3 BD1 and BRD3 BD2 with K<sub>i</sub> values of 11.97 nM and 2.35 nM, respectively<sup>[1]</sup>.</p> <p>GXF-111 has cellular activities in MV4-11 and MM.1 S cell lines with IC<sub>50</sub> values of 6.31 nM and 95.2 nM, respectively<sup>[1]</sup>.</p> <p>GXF-111 (2, 10 nM; 24 h) has potent cell growth inhibition activities for degradation of BET family proteins in MM.1 S cells<sup>[1]</sup>.</p> <p>GXF-111 (4 days) has anti-proliferative activity in 7 human cancer cell lines with IC<sub>50</sub> values range from 6.31 nM to 17.25 μM<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MM.1 S cells, MM.1 S, HGC-27, and MCF-7 cells, Multiple cancer cell lines</td> </tr> <tr> <td>Concentration:</td> <td>2, 10 nM; 0.1, 0.3, 1, 3 nM; 30 nM; 3, 10, 30, 100, 300 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h; 8 h; 1, 3, 6, 8, 24 h; 24 h</td> </tr> <tr> <td>Result:</td> <td>Efficiently depleted BRD3 and BRD4-L in MM.1 S cells at 2 nM. Dose-dependently depleted BRD3 and BRD4-L and partially depleted BRD2 at 10 nM. Had good degradation kinetics of BET proteins in three selected cancer cell lines, i.e. MM.1S, MCF-7, and HGC-27 cells. Only BRD3 and BRD4-L, were depleted dose-dependently in five cancer cell lines, i.e. HGC27, MCF-7, A549, HeLa, and HepG2 cells.</td> </tr> </table> <p>Cell Cycle Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MM.1 S cell</td> </tr> <tr> <td>Concentration:</td> <td>1, 3, 10, 30, 100, 300 nM</td> </tr> </table>	Cell Line:	MM.1 S cells, MM.1 S, HGC-27, and MCF-7 cells, Multiple cancer cell lines	Concentration:	2, 10 nM; 0.1, 0.3, 1, 3 nM; 30 nM; 3, 10, 30, 100, 300 nM	Incubation Time:	24 h; 8 h; 1, 3, 6, 8, 24 h; 24 h	Result:	Efficiently depleted BRD3 and BRD4-L in MM.1 S cells at 2 nM. Dose-dependently depleted BRD3 and BRD4-L and partially depleted BRD2 at 10 nM. Had good degradation kinetics of BET proteins in three selected cancer cell lines, i.e. MM.1S, MCF-7, and HGC-27 cells. Only BRD3 and BRD4-L, were depleted dose-dependently in five cancer cell lines, i.e. HGC27, MCF-7, A549, HeLa, and HepG2 cells.	Cell Line:	MM.1 S cell	Concentration:	1, 3, 10, 30, 100, 300 nM
Cell Line:	MM.1 S cells, MM.1 S, HGC-27, and MCF-7 cells, Multiple cancer cell lines												
Concentration:	2, 10 nM; 0.1, 0.3, 1, 3 nM; 30 nM; 3, 10, 30, 100, 300 nM												
Incubation Time:	24 h; 8 h; 1, 3, 6, 8, 24 h; 24 h												
Result:	Efficiently depleted BRD3 and BRD4-L in MM.1 S cells at 2 nM. Dose-dependently depleted BRD3 and BRD4-L and partially depleted BRD2 at 10 nM. Had good degradation kinetics of BET proteins in three selected cancer cell lines, i.e. MM.1S, MCF-7, and HGC-27 cells. Only BRD3 and BRD4-L, were depleted dose-dependently in five cancer cell lines, i.e. HGC27, MCF-7, A549, HeLa, and HepG2 cells.												
Cell Line:	MM.1 S cell												
Concentration:	1, 3, 10, 30, 100, 300 nM												

---

Incubation Time:	24 h
Result:	Dose-dependently induced cell cycle arrest at G1 phase.

---

## REFERENCES

---

[1]. Yan Z, et al. Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines. Eur J Med Chem. 2023;254:115381.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA